Mesoblast completes Phase 3 low back pain trial treatment as pivotal readout approaches
Mesoblast has completed treatment of 350 patients in its pivotal Phase 3 trial for chronic low back pain, with results expected in mid-2027.
Market Cap $248.2M
!
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Last update - 16.10pm 17/08/2026 (20 minute delay)
?
| Day | ||||||||
|---|---|---|---|---|---|---|---|---|
| Open | 2.6¢ | Day High | 2.7¢ | Day Low | 2.6¢ | |||
| Daily Volume | 4221445 | |||||||
| Bids | Sellers | |||||
|---|---|---|---|---|---|---|
| Number | Price | Volume | Number | Price | Volume | |
| 0 | 2.6¢ | 15692142 | 0 | 2.7¢ | 10348222 | |
Directors & Senior Management
| Mr. Adam Handley | Executive Chairman |
| Ms. Angela Glover | Chief Operating Officer |
| Ms. Belinda Pearce | Financial Controller |
| Mr. Bin Cai | Non-Executive Director |
| Mr. Dale Richards | Head of Technical Services |
| Mr. David Collins | Chief Financial Officer |
| Mr. Enping Fu | Director |
| Mr. Gareth Fleming | Project Director |
| Ms. Hayley Patton | Head of People & Culture |
| Ms. Joanna Yan | Non-Executive Director |
| Mr. Kurt Warburton | Exploration Manager |
| Mr. Liangbing Yu | Independent Non-Executive Director |
| Ms. Lucy Rowe | Joint Company Secretary |
| Ms. Maria Clemente | Joint Company Secretary |
| Mr. Shane Anthony Hartwig | MD, CEO & Director |
Data source: ADVFN
